A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis
Latest Information Update: 07 Dec 2021
Price :
$35 *
At a glance
- Drugs Tocilizumab (Primary) ; Glucocorticoids
- Indications Takayasu syndrome
- Focus Therapeutic Use
- Acronyms TAKT study
- Sponsors Chugai Pharmaceutical
- 05 Jun 2021 Results post hoc analysis (n=28) evaluating vascular imaging in patients with refractory takayasu arteritis, presented at the 22nd Annual Congress of the European League Against Rheumatism
- 17 Jan 2020 Results assessing Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis published in the Rheumatology
- 09 Feb 2018 Status changed from active, no longer recruiting to completed.